A debilitating side effect of cancer radiation may have a switch that doctors can one day turn off. Researchers have identified a previously unknown mechanism behind radiation-induced lung damage: high levels of the signalling protein IFN-beta drive a transformation in immune cells — a shift known as ILC2-to-ILC1 plasticity — that promotes inflammation and fibrosis in healthy lung tissue, according to a study published in Nature Communications and reported by MedicalXpress on October 20.
'Our findings shed light on a previously unknown mechanism that leads to radiation-induced lung damage,' the team said. The work matters because lung injury and the permanent scarring that can follow it limit how aggressively clinicians can treat cancers in and around the chest, and they weigh especially heavily on patients who already live with chronic lung conditions.
The third arm of the research tested the intervention directly. In mice, disrupting the IFN-beta signalling pathway during radiation reduced inflammation, limited lung injury and decreased the fibrosis that permanently scars healthy tissue. 'Our findings suggest that high levels of IFN-beta contribute to the development of lung damage during radiation and that blocking this signaling pathway could offer a potential treatment to reduce this debilitating side effect,' said Jaeho Kim, M.D., Ph.D., first author of the study and a radiation oncology postdoctoral fellow at City of Hope.
If the approach proves effective in people, the researchers say, it could protect patients from long-term lung damage, expand radiation options for individuals with chronic lung conditions such as COPD, and enable more aggressive radiation treatment when a cancer demands it. The findings are pre-clinical — mouse results do not always translate to patients — but they give drug developers a defined target and a defined pathway to test.



